Histologic Outcomes With Vedolizumab vs Adalimumab in Ulcerative Colitis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Gastroenterology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Histologic Outcomes With Vedolizumab Versus Adalimumab in Ulcerative Colitis: Results From VARSITY
Gastroenterology 2021 Jun 15;[EPub Ahead of Print], L Peyrin-Biroulet, EV Loftus, JF Colombel, S Danese, R Rogers, JD Bornstein, J Chen, S Schreiber, BE Sands, RA LirioFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.